Cadila launches Remdesivir in India at Rs 2,800 per vial

Drug firm Zydus Cadila on Thursday said it has launched Remdesivir under the brand name Remdac, used to treat patients suffering from severe symptoms of COVID-19, in the Indian market.  ......

More Covid vaccine candidates get approval for clinical trials in India

Ahmedabad-based Zydus Cadila, Bharat Biotech’s intra-nasal candidate are among the candidates who got approval from the expert panel to conduct clinical trials, Sohini Das reports.......

Covid vaccines for children likely by Sept: AIIMS chief

Trials for Bharat Biotech's Covid-19 vaccine Covaxin on children are underway and results are expected to be released by September, All India Institute of Medical Sciences director Randeep Guleria......

3 lakh remdesivir to be produced daily in 15 days: Govt

The government plans to double the production of antiviral drug remdesivir to around 3 lakh vials per day over the next 15 days, to make it available readily for the treatment of COVID-19.......

Cadila Pharma likely to go public

Indravadan A Modi, chairman of the Ahmedabad-based pharmaceutical major Cadila Pharmaceuticals, gave an indication for the first time on Friday that the company will go public in the near......

Cadila to market anti-cancer drug by 2006

Cadila Pharmaceuticals Ltd on Monday said it would market anti-cancer drugs GCS (Granulocyte Colony Stimulating) Factor and GMCS (Granulocyte Macrophage Colony Stumating) Factor by 2006 end."The......

Cadila plans captive units in PhaEZ Park

Cadila Pharmaceuticals has chalked out ambitious plans to set up close to eight units in its upcoming PhaEZ Park near Ahmedabad, which is touted to be the largest in India. "In all, we will invest......

Cadila Pharma to enter skin care segment

The Ahmedabad-based Rs 550 crore (Rs 5.5 billion) Cadila Pharmaceuticals Lid has introduced its first skincare product, 'Umrela,' on Tuesday. The new launch is part if its strategy to enter the Rs......